

Shasun Chemicals to set up new facilities in Piscataway, US

Chennai, January 28, 2008: Shasun Chemicals & Drugs Ltd; a leading Indian CRAMS and API exporting pharmaceutical company, today announced that it is setting up a process development facility in Piscataway (New Jersey), United States. The facility will be scaled to provide direct Active Pharmaceutical Ingredients (API's) development services in the pre-clinical and clinical trial stages to customers in North America and to extend backend support to the CRAMS partners in the same geography.

This development will further enhance and expand Shasun Chemical's current capacity to provide global clients a seamless range of services from cutting R&D to large scale manufacture and analytical development. With Piscataway operation being situated at the heart of emerging markets, it will help Shasun Chemicals to expand the offering to existing clients and attracting new clients with a broad range of leading expertise and technologies.

The first phase new facility will be operational from April 2008 and represents significant investment in terms of both long-term financial commitment and the creation of almost 50 new, highly skilled jobs. Further growth is also planned and moving to full capacity from October 2009.

Commenting on the development, Kevin Cook, Director (Operations), Shasun Pharma Solutions UK said; "The US facility will allow us to provide North American customers with a local service offering to compliment our existing sites in Europe and India."

Dr Michel Spagnol, Chief Technology Officer of Shasun continued; "The development will also enhance our position as the leading chemistry services provider with both eastern and western facilities."

Adds Mr. Vimal Kumar, Whole Time Director, Shasun Chemicals, said, "In terms of our increasing global presence we feels that the strategic position in the North-West United States will also create a number of new opportunities in the rapidly expanding North American market and strengthen its existing global network with a project pipeline expanding across the west coast United States and Europe."



About Shasun Chemicals & Drugs Ltd. (BSE: 524552, NSE: SHASUNCHEM)

Shasun Chemicals and Drugs Ltd., India is a premier service provider to the pharmaceutical industry. It was founded in 1976 and its headquarters are in Chennai, Tamilnadu, India. Shasun offers an integrated business model by offering services in research, development and manufacturing (including Contract Research and Manufacturing Services). With the maiden acquisition of business and assets of UK-based Rhodia Pharma through the wholly owned subsidiary Shasun Pharma Solutions Ltd. (SPSL), Shasun has now become a multi national company. SPSL has two manufacturing plants, in Dudley and Annan, both located in UK and has 18 commercial/launched products under its belt and 17 molecules under phase II and phase III waiting for commercial approval and launch by its partners. The acquisition would also help Shasun develop a global presence in APIs, custom synthesis and contract manufacturing as the transaction includes all of Rhodia's development and custom manufacturing services catering to innovator and emerging pharmaceutical clients in US, Europe and Asia.

For more information, contact:

Rakesh Sharma/ Neha Goenka
Adfactors PR, Mumbai

Tel: 91- 22- 22813565
Cell: 98214 19263/ 98208 42363
Email: rakesh@adfactorspr.com/
ha.goenka@adfactorspr.com

S. Vimal Kumar
ShasunChemicals&
Drugs Limited
Tel: 91- 44 - 24316700
Fax: 91- 44 - 24348924
Email: vimal@shasun.com